Name: Clarithromycin
Price: 196.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Clarithromycin, is a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, might build the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies. Among 28,484 medicines of clarithromycin, 2317 persons were co-presented to statins. Co-organization of CYP3A4 metabolized statins and clarithromycin was connected with a 2.11 fold expanded danger of death or hospitalization (95 % certainty interim [CI]: 1.79-2.48). This impact was clarified by age, proof of cardiovascular malady, diabetes mellitus and use of different anti-infection agents (multivariable balanced danger proportion: 1.02, 95 % CI: 0.85-1.22). The affectability examinations did not change the noteworthiness of effect. The danger for hospitalization or passing in persons accepting clarithromycin increments with age and cardiovascular disease yet is not causally connected with statin-clarithromycine co-organization.
- Properties
  - Alternative Name
    
    6-((4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-((5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
    
    CAS Number
    
    81103-11-9
    
    Molecular Formula
    
    C38H69NO13
    
    Molecular Weight
    
    747.95
    
    Appearance
    
    A solid
    
    Purity
    
    99.39%
    
    Solubility
    
    ≥31.2 mg/mL in DMSO; insoluble in H2O; ≥3.24 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

Clarithromycin

Clarithromycin

Background

We Also Recommend

PF-2545920

Pioglitazone HCl

Vardenafil HCl Trihydrate